Upstream Bio Files 8-K on Financial Results, Exhibits
Ticker: UPB · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0002022626
| Field | Detail |
|---|---|
| Company | Upstream Bio, Inc. (UPB) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-filing
TL;DR
**Upstream Bio just dropped an 8-K on financial results; get ready for potential stock movement.**
AI Summary
Upstream Bio, Inc. filed an 8-K on March 26, 2026, reporting on Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financial Statements and Exhibits." This filing indicates that the company is likely releasing its financial results, which could significantly impact its stock price depending on whether the results meet or miss market expectations. Investors should pay close attention to the accompanying exhibits, particularly EX-99.1, for the detailed financial information.
Why It Matters
This filing signals the release of Upstream Bio's financial performance, which is crucial for investors to assess the company's health and future prospects. The details in the exhibits will directly influence stock valuation.
Risk Assessment
Risk Level: medium — The risk level is medium because the filing indicates financial results are being released, which can lead to significant stock volatility depending on the actual numbers.
Analyst Insight
A smart investor would immediately locate and review the EX-99.1 exhibit to understand the detailed financial results and compare them against analyst expectations and previous periods to assess Upstream Bio's performance and future outlook.
Key Players & Entities
- Upstream Bio, Inc. (company) — the filer of the 8-K
- 0002022626 (company) — Upstream Bio's CIK
- 2026-03-26 (date) — the filing date and period of report
- Item 2.02 (person) — Results of Operations and Financial Condition
- Item 9.01 (person) — Financial Statements and Exhibits
FAQ
What is the purpose of this 8-K filing by Upstream Bio, Inc.?
This 8-K filing by Upstream Bio, Inc. is primarily to report on "Results of Operations and Financial Condition" under Item 2.02 and to provide "Financial Statements and Exhibits" under Item 9.01, indicating the release of their financial performance.
When was this 8-K filing submitted and accepted by the SEC?
The 8-K filing was submitted and accepted by the SEC on March 26, 2026, at 07:05:07.
What specific exhibits are mentioned in this filing that investors should review?
Investors should review EX-99.1, which is described as 'upb-ex99_1.htm', as it likely contains the detailed financial information related to the 'Results of Operations and Financial Condition'.
What is Upstream Bio, Inc.'s CIK number and business address?
Upstream Bio, Inc.'s CIK number is 0002022626, and its business address is 890 WINTER STREET, SUITE 200, WALTHAM MA 02451.
What is the SIC code for Upstream Bio, Inc. and what does it signify?
Upstream Bio, Inc.'s SIC code is 2834, which stands for 'Pharmaceutical Preparations'. This signifies that the company operates in the pharmaceutical industry.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2026-03-26 07:05:07
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share UPB The Nasdaq
Filing Documents
- upb-20260326.htm (8-K) — 45KB
- upb-ex99_1.htm (EX-99.1) — 246KB
- 0001193125-26-125057.txt ( ) — 416KB
- upb-20260326.xsd (EX-101.SCH) — 26KB
- upb-20260326_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 26, 2026, Upstream Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by Upstream Bio, Inc. on March 26, 2026, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Upstream Bio, Inc. Date: March 26, 2026 By: /s/ E. Rand Sutherland E. Rand Sutherland, M.D. Chief Executive Officer